GlassScriptPhysician profile
Daniel George Paterson
NPI 1497774178
$5,983.47
in general payments reported to CMS, 2019-2025
53 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $717 · 2021: $577 · 2022: $1,152 · 2023: $640 · 2024: $1,125 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.11 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $591.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $585.61 | 2019-2025 | |
| Amgen INC. | $477.30 | 2019-2025 | Tepezza, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $328.66 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.67 | 2019-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $234.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $232.58 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $225.79 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $217.13 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $216.98 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $215.64 | 2024-2025 | Rexulti |
| Abbott Laboratories | $212.42 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $186.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Radius Health, INC. | $165.83 | 2019-2025 | Tymlos |
| Beta Bionics, INC. | $145.18 | 2024 | Ilet Bionic Pancreas |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Paterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.